02126 JW THERAP-B
- 1.320
- 0.0000.00%
JW THERAP-B News
Express News | JW (Cayman) Therapeutics - Pwc Has Tendered Resignation to Board as Auditor
JW (Cayman) Therapeutics Co. Ltd (HKG:2126) Stock Rockets 31% But Many Are Still Ignoring The Company
JW THERAP-B: 2024 INTERIM REPORT
Pharmaron -B (02126) fell 42.80%, now at 1.300 yuan, hitting a 52-week low.
As of 11:34, Wuxi Apptec -B (02126) fell by 42.80% from the previous closing price to 1.300 yuan, hitting a 52-week low; the volume was 0.0227 million shares, with a turnover of 0.0294 million Hong Kong dollars.
WuXi AppTec-B (02126) granted a total of 2.0391 million share purchase rights and a total of 0.6696 million restricted share units.
WuXi AppTec-B (02126) announced in a notice that on September 2, 2024, in accordance with October 14, 2020...
WuXi Biologics-B (02126) appointed Chen Bingjun as an independent non-executive director.
Pharmaron-B (02126) announced that Chen Bingjun has been appointed as an independent non-executive director, effective from August 2, 2024...
WuXi AppTec Group (02126) released its interim performance, achieving revenue of 86.815 million yuan. Leading product BeiNuoDa has continued to make significant progress in commercialization.
WuXi AppTec-B (02126) released the interim performance for the six months ended June 30, 2024, the group's period...
Express News | JW (Cayman) Therapeutics H1 Revenue RMB 86.8 Million
Express News | JW (Cayman) Therapeutics H1 Gross Margin 50.4%
Express News | JW (Cayman) Therapeutics H1 Gross Profit RMB 43.7 Million
Express News | JW (Cayman) Therapeutics H1 Net Income RMB -240.3 Million
JW THERAP-B: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024
JW (Cayman) Therapeutics Co. Ltd (HKG:2126) Might Not Be As Mispriced As It Looks After Plunging 27%
JW Therapeutics Announces NMPA Approval of the Supplemental Biological License Application for Carteyva in Adult Patients With Relapsed or Refractory Mantle Cell Lymphoma
Express News | JW (Cayman) Therapeutics - Nmpa Approved Supplemental Biological License Application for Anti-Cd19 Autologous Chimeric Antigen Receptor T Product
WuXi AppTec-B (02126.HK) plans to hold a board of directors meeting on August 28th to approve mid-term performance.
On August 14th, Gelonghui reported that Pharma Giant-B (02126.HK) announced that the board of directors' meeting will be held on Wednesday, August 28, 2024, to (including) (i) consider and approve the unaudited interim results of the group for the six months ending June 30, 2024 and their publication; and (ii) handle any other matters.
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
WuXi AppTec-B (02126.HK) appointed Liu Min as Executive President and Executive Director.
On July 31, Gelonghui -B (02126.HK) announced that Mr. Liu Min has been appointed as the company's Executive President and Executive Director, effective from July 31, 2024. Mr. Liu will lead the group, focusing on innovation, strategic cooperation, excellent operation, and creating long-term value for all stakeholders. Dr. Yiping James Li, the company's Executive Director and Chief Executive Officer, resigned as the company's Executive Director due to his desire to devote more time to his family and other personal interests, effective July 31, 2024. The Board of Directors has reappointed Dr. Li as a non-executive director.
Express News | JW (Cayman) Therapeutics - Yiping James Li an Executive Director and CEO Resigned as Chief Executive Officer
Express News | JW (Cayman) Therapeutics - Min Liu Appointed as CEO of Company and as Executive Director
Analysis
Price Target
No Data
No Data